Cutaneous natural killer (NK) / T-cell lymphoma: nasal type with extensive facial destruction.
Kost Al
Milan
M
2nd Department of Internal Medicine, Teaching Hospital, Hradec Králové, Czech Republic.
Kost Alová
Marie
M
Belada
David
D
Laco
Jan
J
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018450:Disease Progression; D004317:Doxorubicin / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051359:Lymphohistiocytosis, Hemophagocytic / Q000150:complications; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D055611:Natural Killer T-Cells / Q000276:immunology; D009669:Nose Neoplasms / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000473:pathology*; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone